Icon

TIVICAY (nda204790)- (EQ 50MG BASE,EQ 10MG BASE,EQ 25MG BASE)

DOLUTEGRAVIR SODIUM VIIV HLTHCARE
EQ 50MG BASE,EQ 10MG BASE,EQ 25MG BASE
Yes No
2030-Jun-08 2018-Aug-12
None None
None No
TIVICAY is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.
0 12 0
Total Other Developers 22
Drugs with Suitability No
EQ 50MG BASE ** ** Up - -
EQ 10MG BASE ** ** - - -
EQ 25MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.